èæ¯ 18F-FDG PET/CTå©ç¨å¾åèåææ¯,坿¾ç¤ºåè½ä»£è°¢å¼å¸¸åç»æçæ¹å,ä½å
¶å¨è¸è
ºæ·å·´ç¤é´å«è¯æ,åæåååä¸çä½ç¨ç ç©¶ä»ç¸å¯¹è¾å°.ç®ç æ¢è®¨è¸è
ºæ·å·´ç¤ç18F-FDG PET/CTä»£è°¢åæ°ä¸å
¶ç
çååå临åºåæçå
³ç³».æ¹æ³ éå2015å¹´1æ-2022å¹´5æäºè§£æ¾åæ»å»é¢ä¸ä¸å¿æ ¸å»å¦ç§è¡PET/CTæ£æ¥åç
çå¦è¯å®ä¸ºè¸è
ºæ·å·´ç¤çæ£è
,è®°å½è¸è
ºæ·å·´ç¤ç
ç¶æå¤§æ åæåå¼(maximum standard uptake value,SUVmax),å¹³åæ åæåå¼(mean standard uptake value,SUVmean),代谢ä½ç§¯(metabolic tumor volume,MTV),ç
ç¶ç³é
µè§£æ»é(total lesion glycolysis,TLG)åè¿ç¤-æ£å¸¸èç»ç»æ åæå弿¯å¼(tumor-to-normal liver standard uptake value ratio,SUVR).以æ·å·´ç»åç»å¤å¨å®åç´¯ç»æè¿è¡Ann Arboråæ,å¹¶æ ¹æ®ä¸»è¦ç
çç±»åè¿è¡åç».对18F-FDG PET/CTä»£è°¢åæ°ä¸ä¸´åºç
çåå,åæçç¸å
³æ§è¿è¡åæ.ç»æ å
±è®¡85便£è
纳å
¥ç ç©¶,ç·æ§46ä¾,女æ§39ä¾,å¹´é¾(30.34±14.48)å².å
¶ä¸ååæ§çºµé大Bç»èæ·å·´ç¤(primary mediastinal large B-cell lymphoma,PMBCL) 35ä¾,ç»è硬ååéå¥éæ·å·´ç¤(nodular sclerosis Hodgkin lymphoma,NSHL)29ä¾,Tæ·å·´æ¯ç»èæ·å·´ç¤(T-cell lymphoblastic lymphoma,T-LBL) 19ä¾.Ann Arboråæ:â
æ2ä¾,â
¡æ29ä¾,â
¢æ10ä¾,â
£æ44ä¾.PMBCL,NSHL,T-LBLä¸ç»é´åé¡¹ä»£è°¢åæ°çå·®å¼åæç»è®¡å¦æä¹(P<0.05).ä¸åAnn Arboråæé´åä»£è°¢åæ°å·®å¼åæç»è®¡å¦æä¹(P<0.05).è¸è
ºæ·å·´ç¤Ann Arboråæä¸åé¡¹ä»£è°¢åæ°å忣ç¸å
³(TLG:rs=0.494,P<0.01;MTV:rs=0.469,P<0.01;SUVR:rs=0.378,P<0.01;SUVmax:rs=0.296,P=0.006;SUVmean:rs=0.273,P=0.012).ç»è®º ä¸åç
çç±»åè¸è
ºæ·å·´ç¤ç18F-FDG PET/CTä»£è°¢åæ°åå¨ä¸å®å·®å¼,ä»£è°¢åæ°TLG,MTV,SUVRä¸è¸è
ºæ·å·´ç¤Ann Arboråæä¸åº¦ç¸å
³,å¯ä¸ºä¸´åºå¶å®æ²»ç计åæä¾åè.